Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Bought by AQR Capital Management LLC

AQR Capital Management LLC grew its position in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 90.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 611,798 shares of the life sciences company’s stock after purchasing an additional 291,326 shares during the quarter. AQR Capital Management LLC owned approximately 0.78% of Integra LifeSciences worth $17,436,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. The Manufacturers Life Insurance Company boosted its holdings in Integra LifeSciences by 36.6% in the fourth quarter. The Manufacturers Life Insurance Company now owns 715,294 shares of the life sciences company’s stock valued at $31,151,000 after purchasing an additional 191,529 shares in the last quarter. Burgundy Asset Management Ltd. acquired a new position in shares of Integra LifeSciences in the 4th quarter valued at $237,000. Capital Research Global Investors grew its position in shares of Integra LifeSciences by 40.1% in the 4th quarter. Capital Research Global Investors now owns 4,297,326 shares of the life sciences company’s stock valued at $187,149,000 after buying an additional 1,228,996 shares during the last quarter. Seven Eight Capital LP purchased a new position in shares of Integra LifeSciences in the 4th quarter valued at $1,615,000. Finally, Vista Investment Management acquired a new stake in Integra LifeSciences during the 4th quarter worth $224,000. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Stock Performance

NASDAQ:IART opened at $17.50 on Wednesday. The firm has a market cap of $1.38 billion, a price-to-earnings ratio of 35.00, a price-to-earnings-growth ratio of 0.60 and a beta of 1.10. The company has a debt-to-equity ratio of 1.17, a current ratio of 3.39 and a quick ratio of 2.10. Integra LifeSciences Holdings Co. has a 1-year low of $16.96 and a 1-year high of $45.42. The firm’s fifty day moving average price is $20.78 and its 200 day moving average price is $26.90.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Monday, July 29th. The life sciences company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.01. The business had revenue of $418.20 million for the quarter, compared to the consensus estimate of $413.07 million. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The business’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.71 earnings per share. On average, sell-side analysts expect that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have issued reports on IART. Truist Financial dropped their price objective on Integra LifeSciences from $32.00 to $26.00 and set a “hold” rating on the stock in a report on Tuesday, July 30th. JMP Securities cut their price target on Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating on the stock in a research report on Tuesday, July 30th. Citigroup reduced their price objective on Integra LifeSciences from $20.00 to $16.00 and set a “sell” rating for the company in a research note on Tuesday. Morgan Stanley raised their target price on shares of Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a research report on Monday, July 15th. Finally, BTIG Research reduced their price target on shares of Integra LifeSciences from $22.00 to $20.00 and set a “sell” rating for the company in a research report on Wednesday, August 28th. Four equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, Integra LifeSciences has a consensus rating of “Hold” and an average target price of $28.13.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.